Nicola Heffron
Ventas & Marketing en ALEXION PHARMACEUTICALS, INC. .
Fortuna: 106 643 $ al 31/05/2024
Perfil
Nicola Heffron is a professional with experience in the pharmaceutical industry.
She is currently the Senior VP, Head-Global Marketing & Market Access at Alexion Pharmaceuticals, Inc. Her former positions include Head-Global Marketing at Celgene Corp.
in 2018, Chief Commercial Officer at bluebird bio, Inc. from 2020 to 2021, and Chief Operating Officer at 2seventy Bio, Inc. from 2021 to 2023.
Ms. Heffron holds an MBA from the University of Warwick.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
2SEVENTY BIO, INC.
0.05% | 13/04/2023 | 25 211 ( 0.05% ) | 106 643 $ | 31/05/2024 |
Cargos activos de Nicola Heffron
| Empresas | Cargo | Inicio |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Ventas & Marketing | 01/04/2023 |
Antiguos cargos conocidos de Nicola Heffron.
| Empresas | Cargo | Fin |
|---|---|---|
| 2SEVENTY BIO, INC. | Director de Operaciones | 10/03/2023 |
| CELGENE | Ventas & Marketing | 01/09/2018 |
| BLUEBIRD BIO, INC. | Corporate Officer/Principal | - |
Formación de Nicola Heffron.
| University of Warwick | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| 2SEVENTY BIO, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Nicola Heffron
